Charles River Laboratories International, Inc. Files 2023 Annual Report

TL;DR

<b>Charles River Laboratories International, Inc. has filed its 2023 10-K annual report detailing its operations and financial standing.</b>

AI Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed a Annual Report (10-K) with the SEC on February 14, 2024. Charles River Laboratories International, Inc. filed its 10-K report for the fiscal year ending December 30, 2023. The company operates in the Services - Commercial Physical & Biological Research sector, SIC code 8731. The filing covers the period from January 1, 2023, to December 30, 2023. Key financial data from previous fiscal years (2020-2022) is referenced in the filing. The company's principal business address is 251 Ballardvale St, Wilmington, MA 01887.

Why It Matters

For investors and stakeholders tracking CHARLES RIVER LABORATORIES INTERNATIONAL, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Charles River Laboratories' financial performance and business operations for the fiscal year 2023, crucial for investors assessing the company's health and future prospects. The detailed financial data and disclosures within the report are essential for understanding the company's revenue streams, expenses, assets, liabilities, and equity, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shows moderate risk based on this filing. The filing is a standard 10-K, which is a comprehensive annual report. While it contains detailed financial information, it does not inherently signal immediate positive or negative performance trends without further analysis of the specific figures and management discussion.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-K to identify specific revenue growth drivers, cost management strategies, and any emerging risks or opportunities.

Key Numbers

• 2023-12-30 — Fiscal Year End (Reporting period)
• 2024-02-14 — Filing Date (Date of submission)
• 001-15943 — SEC File Number (SEC registration number)
• 0001100682-24-000007 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — Filer name
• CRL (company) — Ticker symbol
• 2023-12-30 (date) — Fiscal year end
• 2024-02-14 (date) — Filing date
• 8731 (other) — Standard Industrial Classification code
• 251 Ballardvale St, Wilmington, MA 01887 (address) — Business address

FAQ

Industry Context

Charles River Laboratories operates within the commercial physical and biological research services sector, providing essential products and services to pharmaceutical, biotechnology, and medical device companies.

Regulatory Implications

The filing is a 10-K, an annual report required by the U.S. Securities and Exchange Commission (SEC) for publicly traded companies.

What Investors Should Do

1. Analyze the detailed financial statements (income statement, balance sheet, cash flow statement) for the fiscal year 2023.
2. Review the Management's Discussion and Analysis of Financial Condition and Results of Operations section for insights into performance drivers and trends.
3. Examine any disclosed risk factors or legal proceedings that could impact the company's future operations.

Key Dates

• 2023-12-30: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-14: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year 2023. Previous filings would be for earlier fiscal years.

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value CRL New York Stock Exchange
• $2.5 billion — it takes between 10 to 15 years, up to $2.5 billion excluding time costs and exploration of
• $4.1 billion — esearch. In 2023, our total revenue was $4.1 billion. We have three reportable segments: Re

Filing Documents

• crl-20231230.htm (10-K) — 2868KB
• crl1230202310-kex102.htm (EX-10.2) — 142KB
• crl1230202310-kex106.htm (EX-10.6) — 31KB
• crl1230202310-kex19.htm (EX-19) — 116KB
• crl1230202310-kex211.htm (EX-21.1) — 61KB
• crl1230202310-kex231.htm (EX-23.1) — 2KB
• crl1230202310-kex311.htm (EX-31.1) — 9KB
• crl1230202310-kex312.htm (EX-31.2) — 9KB
• crl1230202310-kex321.htm (EX-32.1) — 7KB
• crl1230202310-kex97.htm (EX-97) — 54KB
• crl-20231230_g1.jpg (GRAPHIC) — 6KB
• crl-20231230_g2.jpg (GRAPHIC) — 83KB
• image_01.jpg (GRAPHIC) — 104KB
• image_0a.jpg (GRAPHIC) — 4KB
• picture1.jpg (GRAPHIC) — 12KB
• 0001100682-24-000007.txt (&nbsp;) — 17436KB
• crl-20231230.xsd (EX-101.SCH) — 95KB
• crl-20231230_cal.xml (EX-101.CAL) — 157KB
• crl-20231230_def.xml (EX-101.DEF) — 478KB
• crl-20231230_lab.xml (EX-101.LAB) — 1362KB
• crl-20231230_pre.xml (EX-101.PRE) — 899KB
• crl-20231230_htm.xml (XML) — 3024KB

Signatures

Signatures 109 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. PART I

Business

Item 1. Business General This Annual Report on Form 10-K contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as "expect," "anticipate," "target," "goal," "project," "intend," "plan," "believe," "seek," "estimate," "will," "likely," "may," "designed," "would," "future," "can," "could" and other similar expressions, which are predictions of, indicate future events and trends or which do not relate to historical matters are intended to identify such forward-looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict. For example, we may use forward-looking statements when addressing topics such as: our expectations regarding the availability of non-human primates and our ability to diversify our non-human primate supply chain; the outcome of (1) the U.S. government investigations and inquiries related to the non-human primate supply chain (including shipments of non-human primates from Cambodia received by the Company), (2) the putative securities class action lawsuit filed against us and certain current/former officers on May 19, 2023, and (3) the derivative lawsuit filed against members of the Board of Directors and certain current/former officers on November 8, 2023; the timing and impact of the development and implementation of enhanced procedures to reasonably ensure that non-human primates we source are purpose-bred; changes and uncertainties in the global economy and financial markets, including any changes in business, political, or economic conditions due to the November 16, 2022 announcement by the U.S. Department of Justice through the U.S. Attorney's Office for the Southern Distr

View Full Filing

View this 10-K filing on SEC EDGAR